Athira Pharma, Inc.

Biotechnology • Healthcare • Bothell, WA, United States • ATHA (NCM)

425 620 8501 18706 North Creek Parkway, Bothell, WA 98011, United States

Quarter: Q4 2025 Reported: November 6, 2025 Sentiment: Neutral

Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Analysis Summary

Athira Pharma, Inc. (ATHA) formally disclosed its financial results for the third quarter, ending September 30, 2025, through a press release dated November 6, 2025, as per an SEC filing (Item 2.02). The provided transcript does not contain specific financial performance metrics such as revenue, net income, or EPS, nor does it offer any forward guidance or growth rates. Strategic initiatives, business segment analysis, management commentary, competitive positioning, market trends, and risk factors were not discussed in this particular filing. The company also detailed its comprehensive approach to public disclosure (Item 7.01), listing various official communication channels including SEC filings, its corporate website (www.athira.com), investor relations site (investors.athira.com), news site, and several social media platforms (X, LinkedIn, Instagram, Facebook). This multi-channel strategy is intended to ensure broad dissemination of material information to investors, media, and the public regarding the company and its product candidates. No analyst Q&A highlights were available from this excerpt.

Key Highlights

• Athira Pharma, Inc. announced financial results for Q3 2025 via a press release on November 6, 2025.
• The company utilizes multiple channels for public disclosure, including SEC filings, corporate websites, and social media.
• No specific financial figures (revenue, earnings, EPS) or operational updates were provided in the transcript.
• Material information is disseminated through official company channels to ensure broad access.
• The disclosure primarily highlights the company's communication strategy rather than financial performance.

Financial Metrics

eps

YoY: N/A

revenue

N/A

YoY: N/A

guidance

net income

N/A

YoY: N/A

Stock Performance (90 Days)

Data through Dec 29, 2025

Layoff Events

Earnings Calls

Positive Signals

• Commitment to transparent and multi-channel communication with investors and the public.
• Regular adherence to SEC disclosure requirements (Item 2.02, Item 7.01).
• Proactive use of various digital platforms (social media, dedicated investor sites) to reach a broad audience.

Risks & Concerns

— No specific financial or operational details were provided in the transcript, limiting insight into company performance.
— Reliance on external press releases for detailed financial information, which was not included in this excerpt.
— Lack of forward-looking guidance or strategic updates in the provided text.
— Inability to assess company's financial health or future prospects based solely on this disclosure.